Pravastatin - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (1)Enzymes (5)Transporters (13)

Targets (1)Enzymes (5)Transporters (13)Biointeractions (26)

Identification

Name

Pravastatin

Accession Number

DB00175 (APRD00328)

Type

Small Molecule

Groups

Approved

Description

Pravastatin is a cholesterol-lowering agent that belongs to a class of medications known as statins. It was derived from microbial transformation of mevastatin, the first statin discovered. It is a ring-opened dihydroxyacid with a 6’-hydroxyl group that does not require in vivo activation. Pravastatin is one of the lower potency statins; however, its increased hydrophilicity is thought to confer advantages such as minimal penetration through lipophilic membranes of peripheral cells, increased selectivity for hepatic tissues, and a reduction in side effects compared with lovastatin and simvastatin.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

(+)-(3R,5R)-3,5-Dihydroxy-7-[(1S,2S,6S,8S,8ar)-6-hydroxy-2-methyl-8-{[(S)-2-methylbutyryl]oxy}-1,2,6,7,8,8a-hexahydro-1-naphthyl]heptanoic acid

Pravastatin acid

Pravastatina

Pravastatine

Pravastatinum

External IDs

C10AA03

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Pravastatin Sodium	3M8608UQ61	81131-70-6	VWBQYTRBTXKKOG-NJUCWUMRNA-M	Details

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Ach-pravastatin	Tablet	40 mg	Oral	Accord Healthcare Limited	Not applicable	Not applicable	Canada
Ach-pravastatin	Tablet	20 mg	Oral	Accord Healthcare Limited	Not applicable	Not applicable	Canada
Ach-pravastatin	Tablet	10 mg	Oral	Accord Healthcare Limited	Not applicable	Not applicable	Canada
Act Pravastatin	Tablet	20 mg	Oral	Actavis Pharma Company	2003-12-09	Not applicable	Canada
Act Pravastatin	Tablet	10 mg	Oral	Actavis Pharma Company	2003-12-09	Not applicable	Canada
Act Pravastatin	Tablet	40 mg	Oral	Actavis Pharma Company	2003-12-09	Not applicable	Canada
Auro-pravastatin	Tablet	40 mg	Oral	Auro Pharma Inc	Not applicable	Not applicable	Canada
Auro-pravastatin	Tablet	10 mg	Oral	Auro Pharma Inc	Not applicable	Not applicable	Canada
Auro-pravastatin	Tablet	20 mg	Oral	Auro Pharma Inc	Not applicable	Not applicable	Canada
Ava-pravastatin	Tablet	20 mg	Oral	Avanstra Inc	2011-10-11	2011-12-12	Canada
Ava-pravastatin	Tablet	40 mg	Oral	Avanstra Inc	2011-10-11	2011-12-12	Canada
Ava-pravastatin	Tablet	10 mg	Oral	Avanstra Inc	2011-10-11	2011-12-12	Canada
Bio Pravastatin	Tablet	20 mg	Oral	Bioenhance Medicines Inc.	2001-07-12	2003-02-27	Canada
Bio Pravastatin	Tablet	10 mg	Oral	Bioenhance Medicines Inc.	2001-07-12	2003-02-27	Canada
Bio Pravastatin	Tablet	40 mg	Oral	Bioenhance Medicines Inc.	2001-07-12	2003-02-27	Canada
Bio-pravastatin	Tablet	40 mg	Oral	Biomed Pharma	2016-08-17	Not applicable	Canada
Bio-pravastatin	Tablet	10 mg	Oral	Biomed Pharma	2016-08-17	Not applicable	Canada
Bio-pravastatin	Tablet	20 mg	Oral	Biomed Pharma	2016-08-17	Not applicable	Canada
Dom-pravastatin	Tablet	20 mg	Oral	Dominion Pharmacal	2004-05-12	Not applicable	Canada
Dom-pravastatin	Tablet	40 mg	Oral	Dominion Pharmacal	2004-05-12	Not applicable	Canada
Dom-pravastatin	Tablet	10 mg	Oral	Dominion Pharmacal	2004-05-12	Not applicable	Canada
Ipg-pravastatin	Tablet	40 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Ipg-pravastatin	Tablet	20 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Ipg-pravastatin	Tablet	10 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Jamp-pravastatin	Tablet	40 mg	Oral	Jamp Pharma Corporation	2010-04-01	Not applicable	Canada
Jamp-pravastatin	Tablet	10 mg	Oral	Jamp Pharma Corporation	2010-04-01	Not applicable	Canada
Jamp-pravastatin	Tablet	20 mg	Oral	Jamp Pharma Corporation	2010-04-01	Not applicable	Canada
Lin-pravastatin	Tablet	10 mg	Oral	Linson Pharma Co.	2000-07-13	2006-05-29	Canada
Lin-pravastatin	Tablet	20 mg	Oral	Linson Pharma Co.	2000-07-13	2006-05-29	Canada
Lin-pravastatin	Tablet	40 mg	Oral	Linson Pharma Co.	2000-07-13	2006-05-29	Canada
Mar-pravastatin	Tablet	20 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Mar-pravastatin	Tablet	40 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Mar-pravastatin	Tablet	10 mg	Oral	Marcan Pharmaceuticals Inc	Not applicable	Not applicable	Canada
Mint-pravastatin	Tablet	40 mg	Oral	Mint Pharmaceuticals Inc	2009-02-06	Not applicable	Canada
Mint-pravastatin	Tablet	10 mg	Oral	Mint Pharmaceuticals Inc	2009-02-06	Not applicable	Canada
Mint-pravastatin	Tablet	20 mg	Oral	Mint Pharmaceuticals Inc	2009-02-06	Not applicable	Canada
Mylan-pravastatin	Tablet	20 mg	Oral	Mylan Pharmaceuticals	2005-04-07	Not applicable	Canada
Mylan-pravastatin	Tablet	40 mg	Oral	Mylan Pharmaceuticals	2005-04-07	Not applicable	Canada
Mylan-pravastatin	Tablet	10 mg	Oral	Mylan Pharmaceuticals	2005-04-07	Not applicable	Canada
Ntp-pravastatin	Tablet	40 mg	Oral	Teva	Not applicable	Not applicable	Canada
Ntp-pravastatin	Tablet	10 mg	Oral	Teva	Not applicable	Not applicable	Canada
Ntp-pravastatin	Tablet	20 mg	Oral	Teva	Not applicable	Not applicable	Canada
Nu-pravastatin Tablets	Tablet	20 mg	Oral	Nu Pharm Inc	2002-05-02	2012-09-04	Canada
Nu-pravastatin Tablets	Tablet	40 mg	Oral	Nu Pharm Inc	2002-05-16	2012-09-04	Canada
Nu-pravastatin Tablets	Tablet	10 mg	Oral	Nu Pharm Inc	2002-05-13	2012-09-04	Canada
Pendo-pravastatin	Tablet	20 mg	Oral	Pendopharm Division Of De Pharmascience Inc	Not applicable	Not applicable	Canada
Pendo-pravastatin	Tablet	10 mg	Oral	Pendopharm Division Of De Pharmascience Inc	Not applicable	Not applicable	Canada
PMS-pravastatin	Tablet	10 mg	Oral	Pharmascience Inc	2003-07-21	Not applicable	Canada
PMS-pravastatin	Tablet	20 mg	Oral	Pharmascience Inc	2003-07-21	Not applicable	Canada
PMS-pravastatin	Tablet	40 mg	Oral	Pharmascience Inc	2003-07-21	Not applicable	Canada
Pravachol	Tablet	40 mg/1	Oral	E.R. Squibb & Sons, L.L.C.	2009-06-01	Not applicable	US
Pravachol	Tablet	80 mg/1	Oral	E.R. Squibb & Sons, L.L.C.	2009-06-01	Not applicable	US
Pravachol	Tablet	20 mg/1	Oral	E.R. Squibb & Sons, L.L.C.	2009-06-01	Not applicable	US
Pravachol	Tablet	80 mg	Oral	Bristol Myers Squibb	Not applicable	Not applicable	Canada
Pravachol - Tab 10mg	Tablet	10 mg	Oral	Bristol Myers Squibb	1990-12-31	2017-06-14	Canada
Pravachol - Tab 20mg	Tablet	20 mg	Oral	Bristol Myers Squibb	1990-12-31	Not applicable	Canada
Pravachol - Tab 40mg	Tablet	40 mg	Oral	Bristol Myers Squibb	1996-08-21	Not applicable	Canada
Pravastatin	Tablet	10 mg	Oral	Meliapharm Inc	2004-07-22	2014-06-25	Canada
Pravastatin	Tablet	20 mg	Oral	Sanis Health Inc	2010-11-23	Not applicable	Canada
Pravastatin	Tablet	20 mg	Oral	Sorres Pharma Inc	2009-02-26	2014-06-20	Canada
Pravastatin	Tablet	20 mg	Oral	Cobalt Laboratories	Not applicable	Not applicable	Canada
Pravastatin	Tablet	20 mg	Oral	Sivem Pharmaceuticals Ulc	2012-07-23	Not applicable	Canada
Pravastatin	Tablet	20 mg	Oral	Meliapharm Inc	2004-07-22	2014-06-25	Canada
Pravastatin	Tablet	40 mg	Oral	Sanis Health Inc	2010-12-01	Not applicable	Canada
Pravastatin	Tablet	40 mg	Oral	Sorres Pharma Inc	2009-02-26	2014-06-20	Canada
Pravastatin	Tablet	40 mg	Oral	Cobalt Laboratories	Not applicable	Not applicable	Canada
Pravastatin	Tablet	40 mg	Oral	Sivem Pharmaceuticals Ulc	2012-07-23	Not applicable	Canada
Pravastatin	Tablet	10 mg	Oral	Sanis Health Inc	2010-11-23	Not applicable	Canada
Pravastatin	Tablet	10 mg	Oral	Sorres Pharma Inc	2009-02-26	2014-06-20	Canada
Pravastatin	Tablet	10 mg	Oral	Cobalt Laboratories	Not applicable	Not applicable	Canada
Pravastatin	Tablet	40 mg	Oral	Meliapharm Inc	2004-07-22	2014-06-25	Canada
Pravastatin	Tablet	10 mg	Oral	Sivem Pharmaceuticals Ulc	2012-07-23	Not applicable	Canada
Pravastatin Tablets	Tablet	20 mg	Oral	Ranbaxy Inc.	Not applicable	Not applicable	Canada
Pravastatin Tablets	Tablet	10 mg	Oral	Ranbaxy Inc.	Not applicable	Not applicable	Canada
Pravastatin Tablets	Tablet	40 mg	Oral	Ranbaxy Inc.	Not applicable	Not applicable	Canada
Pravastatin-10	Tablet	10 mg	Oral	Pro Doc Limitee	2002-12-23	Not applicable	Canada
Pravastatin-20	Tablet	20 mg	Oral	Pro Doc Limitee	2002-12-23	Not applicable	Canada
Pravastatin-40	Tablet	40 mg	Oral	Pro Doc Limitee	2002-12-23	Not applicable	Canada
Priva-pravastatin	Tablet	40 mg	Oral	Pharmapar Inc	2016-08-17	Not applicable	Canada
Priva-pravastatin	Tablet	10 mg	Oral	Pharmapar Inc	2016-08-17	Not applicable	Canada
Priva-pravastatin	Tablet	20 mg	Oral	Pharmapar Inc	2016-08-17	Not applicable	Canada
Q-pravastatin	Tablet	40 mg	Oral	Qd Pharmaceuticals Ulc	Not applicable	Not applicable	Canada
Q-pravastatin	Tablet	10 mg	Oral	Qd Pharmaceuticals Ulc	Not applicable	Not applicable	Canada
Q-pravastatin	Tablet	20 mg	Oral	Qd Pharmaceuticals Ulc	Not applicable	Not applicable	Canada
Ran-pravastatin	Tablet	20 mg	Oral	Ranbaxy Inc.	2007-05-16	Not applicable	Canada
Ran-pravastatin	Tablet	10 mg	Oral	Ranbaxy Inc.	2007-05-16	Not applicable	Canada
Ran-pravastatin	Tablet	40 mg	Oral	Ranbaxy Inc.	2007-05-16	Not applicable	Canada
Ratio-pravastatin	Tablet	20 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	2003-02-03	2014-09-19	Canada
Ratio-pravastatin	Tablet	40 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	2003-02-03	2014-09-19	Canada
Ratio-pravastatin	Tablet	10 mg	Oral	Ratiopharm Inc Division Of Teva Canada Limited	2003-02-03	2014-09-19	Canada
Riva-pravastatin	Tablet	20 mg	Oral	Laboratoire Riva Inc	Not applicable	Not applicable	Canada
Riva-pravastatin	Tablet	10 mg	Oral	Laboratoire Riva Inc	2005-10-28	Not applicable	Canada
Riva-pravastatin	Tablet	20 mg	Oral	Laboratoire Riva Inc	2004-10-22	2005-06-30	Canada
Riva-pravastatin	Tablet	10 mg	Oral	Laboratoire Riva Inc	2004-10-22	2005-06-30	Canada
Riva-pravastatin	Tablet	20 mg	Oral	Laboratoire Riva Inc	2005-10-28	Not applicable	Canada
Riva-pravastatin	Tablet	40 mg	Oral	Laboratoire Riva Inc	2004-10-22	2005-06-30	Canada
Riva-pravastatin	Tablet	40 mg	Oral	Laboratoire Riva Inc	Not applicable	Not applicable	Canada
Riva-pravastatin	Tablet	10 mg	Oral	Laboratoire Riva Inc	Not applicable	Not applicable	Canada
Riva-pravastatin	Tablet	40 mg	Oral	Laboratoire Riva Inc	2005-10-28	Not applicable	Canada
Sandoz Pravastatin	Tablet	40 mg	Oral	Sandoz Canada Incorporated	2003-08-12	2017-05-29	Canada
Sandoz Pravastatin	Tablet	10 mg	Oral	Sandoz Canada Incorporated	Not applicable	Not applicable	Canada
Sandoz Pravastatin	Tablet	20 mg	Oral	Sandoz Canada Incorporated	2003-08-12	2017-05-29	Canada
Sandoz Pravastatin	Tablet	20 mg	Oral	Sandoz Canada Incorporated	Not applicable	Not applicable	Canada
Sandoz Pravastatin	Tablet	10 mg	Oral	Sandoz Canada Incorporated	2003-12-08	2017-05-29	Canada
Sandoz Pravastatin	Tablet	40 mg	Oral	Sandoz Canada Incorporated	Not applicable	Not applicable	Canada
Teva-pravastatin	Tablet	20 mg	Oral	Teva	2003-01-08	Not applicable	Canada
Teva-pravastatin	Tablet	40 mg	Oral	Teva	2003-01-08	Not applicable	Canada
Teva-pravastatin	Tablet	10 mg	Oral	Teva	2003-01-08	Not applicable	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-pravastatin	Tablet	20 mg	Oral	Apotex Corporation	2001-02-27	Not applicable	Canada
Apo-pravastatin	Tablet	40 mg	Oral	Apotex Corporation	2001-02-27	Not applicable	Canada
Apo-pravastatin	Tablet	10 mg	Oral	Apotex Corporation	2001-02-27	Not applicable	Canada
Pravastatin	Tablet	80 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Unit Dose Services	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Cardinal Health	2007-05-11	2017-05-11	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Aidarex Pharmaceuticals LLC	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Teva	2008-09-29	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Directrx	2015-12-28	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Dr Reddy's Laboratories	2009-12-31	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Remedy Repack	2011-06-08	2016-10-13	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Remedy Repack	2015-02-20	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2007-05-11	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Physicians Total Care, Inc.	2009-12-11	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	A S Medication Solutions	2011-07-18	2017-06-20	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Cipla Limited	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Golden State Medical Supply	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-08-05	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Cadila Pharnmaceuticals	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Accord Healthcare Limited	2017-01-02	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Apotex Corporation	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Aurobindo Pharma	2017-02-02	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2011-07-22	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Zydus Pharmaceuticals Usa, Inc.	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	International Laboratories, Llc	2009-02-09	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	A S Medication Solutions	2010-03-30	2017-06-20	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Remedy Repack	2016-09-07	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Actavis Pharma Company	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Mylan Pharmaceuticals	2010-05-27	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Citron Pharma LLC	2017-02-02	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Av Kare, Inc.	2014-06-17	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Remedy Repack	2017-03-10	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Major	2010-07-06	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Northwind Pharmaceuticals	2014-07-10	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	bryant ranch prepack	2006-04-25	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Amerincan Health Packaging	2011-10-01	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	A S Medication Solutions	2007-12-28	2017-06-20	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2008-09-29	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2007-05-11	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Remedy Repack	2017-04-12	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	A S Medication Solutions	2007-05-11	2017-06-20	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-05-31	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Rebel Distributors	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Accord Healthcare Limited	2017-01-02	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Aurobindo Pharma	2017-02-02	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2009-12-31	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	International Laboratories, Llc	2008-03-27	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Blenheim Pharmacal, Inc.	2012-02-13	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Remedy Repack	2013-05-23	2016-04-05	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2017-02-16	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Amerincan Health Packaging	2014-05-30	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	State of Florida DOH Central Pharmacy	2013-01-01	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Remedy Repack	2014-10-03	2016-10-13	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Clinical Solutions Wholsesale	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Av Kare, Inc.	2014-06-17	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Sandoz	2014-04-28	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Proficient Rx LP	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Dr Reddy's Laboratories	2009-12-31	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Northwind Pharmaceuticals	2014-11-12	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Lupin Pharmaceuticals	2008-07-24	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2007-05-11	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Av Pak	2016-03-15	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Cardinal Health	2007-05-11	2017-05-11	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Amerincan Health Packaging	2016-06-01	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Teva	2006-04-25	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Remedy Repack	2014-10-03	2016-10-13	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	A S Medication Solutions	2011-07-18	2017-06-20	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Mylan Institutional	2007-10-03	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Med Vantx, Inc.	2006-04-25	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Remedy Repack	2015-02-20	2017-03-17	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Cipla Limited	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Golden State Medical Supply	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Major	2008-08-01	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	bryant ranch prepack	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Cardinal Health	2013-05-24	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Zydus Pharmaceuticals Usa, Inc.	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	A S Medication Solutions	2010-03-30	2017-06-20	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Amerincan Health Packaging	2016-06-01	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Mylan Pharmaceuticals	2010-05-27	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Citron Pharma LLC	2017-02-02	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Aidarex Pharmaceuticals LLC	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Major	2010-07-06	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	bryant ranch prepack	2006-04-25	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Aidarex Pharmaceuticals LLC	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Cobalt Laboratories	2006-10-23	2015-12-29	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Physicians Total Care, Inc.	2006-05-11	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	International Laboratories, Llc	2015-05-01	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Blenheim Pharmacal, Inc.	2014-02-19	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Northwind Pharmaceuticals	2014-11-12	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	bryant ranch prepack	2014-07-28	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Amerincan Health Packaging	2011-10-01	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Cardinal Health	2012-02-10	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Clinical Solutions Wholsesale	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Rebel Distributors	2007-05-11	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Sandoz	2014-04-28	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Directrx	2015-12-28	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Dr Reddy's Laboratories	2009-12-31	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Remedy Repack	2011-09-20	2016-10-13	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Remedy Repack	2015-12-10	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	State of Florida DOH Central Pharmacy	2013-01-01	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2007-12-28	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Cardinal Health	2010-07-06	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	A S Medication Solutions	2011-07-18	2017-06-20	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Teva	2006-04-25	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	St. Marys Medical Park Pharmacy	2013-08-14	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2016-10-17	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Remedy Repack	2011-11-14	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Cadila Pharnmaceuticals	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Accord Healthcare Limited	2017-01-02	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Apotex Corporation	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Nu Care Pharmaceuticals,inc.	2007-05-11	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2011-07-22	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Zydus Pharmaceuticals Usa, Inc.	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	International Laboratories, Llc	2013-04-26	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	A S Medication Solutions	2010-03-30	2017-06-20	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Proficient Rx LP	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Actavis Pharma Company	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Mylan Pharmaceuticals	2010-05-27	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Aurobindo Pharma	2017-02-02	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Av Kare, Inc.	2014-06-17	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Remedy Repack	2013-06-11	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2014-04-28	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2017-02-16	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Rebel Distributors	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2009-12-31	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Remedy Repack	2013-07-01	2016-04-05	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Preferreed Pharmaceuticals Inc.	2013-01-07	2016-10-13	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	International Laboratories, Inc.	2012-02-20	2016-10-13	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Remedy Repack	2015-12-08	2016-10-13	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Clinical Solutions Wholsesale	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Sandoz	2014-07-28	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	bryant ranch prepack	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Cardinal Health	2013-05-24	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Lupin Pharmaceuticals	2008-07-24	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2014-06-17	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Amerincan Health Packaging	2016-06-01	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Physicians Total Care, Inc.	2006-05-11	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Cipla Limited	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Golden State Medical Supply	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Major	2008-08-01	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Cadila Pharnmaceuticals	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Apotex Corporation	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Zydus Pharmaceuticals Usa, Inc.	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	A S Medication Solutions	2007-05-11	2017-06-20	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Remedy Repack	2016-04-22	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Mylan Pharmaceuticals	2010-05-27	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Citron Pharma LLC	2017-02-02	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Unit Dose Services	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Major	2010-07-06	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	bryant ranch prepack	2006-04-25	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Aidarex Pharmaceuticals LLC	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2006-04-25	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Proficient Rx LP	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Actavis Pharma Company	2007-12-28	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Accord Healthcare Limited	2017-01-02	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Aurobindo Pharma	2017-02-02	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Av Kare, Inc.	2014-06-17	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	International Laboratories, Llc	2015-05-01	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Blenheim Pharmacal, Inc.	2012-02-13	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Remedy Repack	2013-05-23	2016-04-05	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Remedy Repack	2017-05-19	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Amerincan Health Packaging	2011-10-01	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	State of Florida DOH Central Pharmacy	2013-01-01	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Cardinal Health	2012-02-10	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Clinical Solutions Wholsesale	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Rebel Distributors	2007-05-11	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Sandoz	2014-04-28	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Proficient Rx LP	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Dr Reddy's Laboratories	2009-12-31	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Remedy Repack	2011-11-30	2016-10-13	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Lupin Pharmaceuticals	2008-07-24	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2007-05-11	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Av Pak	2016-03-15	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Cardinal Health	2008-08-01	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Clinical Solutions Wholsesale	2007-05-11	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Teva	2006-04-25	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	St. Marys Medical Park Pharmacy	2013-08-14	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	A S Medication Solutions	2011-07-18	2017-06-20	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Mylan Institutional	2006-05-22	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Cadila Pharnmaceuticals	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Lake Erie Medical Dba Quality Care Produts Llc	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Apotex Corporation	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	A S Medication Solutions	2006-10-23	2017-06-20	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2007-05-11	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Remedy Repack	2017-04-07	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	A S Medication Solutions	2007-05-11	2017-06-20	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Lupin Pharmaceuticals	2008-07-24	Not applicable	US
Pravastatin Sodium	Tablet	80 mg/1	Oral	Aphena Pharma Solutions Tennessee, Inc.	2014-06-17	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Amerincan Health Packaging	2016-06-01	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Preferred Pharmaceuticals Inc., Usa	2016-11-15	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Citron Pharma LLC	2017-02-02	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2014-04-28	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Nucare Pharmaceuticals, Inc.	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Rebel Distributors	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2010-03-30	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Remedy Repack	2013-11-05	2016-04-05	US
Pravastatin Sodium	Tablet	40 mg/1	Oral	Mc Kesson Contract Packaging	2013-04-12	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Physicians Total Care, Inc.	2007-01-25	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Cipla Limited	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Golden State Medical Supply	2011-07-18	Not applicable	US
Pravastatin Sodium	Tablet	10 mg/1	Oral	Major	2008-08-01	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	bryant ranch prepack	2006-10-23	Not applicable	US
Pravastatin Sodium	Tablet	20 mg/1	Oral	Cardinal Health	2013-05-24	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Elisor	Not Available
Lipostat	Not Available
Mevalotin	Not Available
Pravaselect	Not Available
Selipran	Not Available

Brand mixtures

Name	Labeller	Ingredients
Pal-pravastatin-asa	Paladin Labs Inc	Acetylsalicylic acid Pravastatin

Categories

UNII

KXO2KT9N0G

CAS number

81093-37-0

Weight

Average: 424.5277
Monoisotopic: 424.246103506

Chemical Formula

C₂₃H₃₆O₇

InChI Key

TUZYXOIXSAXUGO-PZAWKZKUSA-N

InChI

InChI=1S/C23H36O7/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28)/t13-,14-,16+,17+,18+,19-,20-,22-/m0/s1

IUPAC Name

(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-{[(2S)-2-methylbutanoyl]oxy}-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid

SMILES

[H][C@]12[[email protected]](C[[email protected]](O)C=C1C=C[[email protected]](C)[C@@H]2CC[C@@H](O)C[C@@H](O)CC(O)=O)OC(=O)[C@@H](C)CC

Pharmacology

Indication

For the treatment of hypercholesterolemia and to reduce the risk of cardiovascular disease.

Structured Indications

Pharmacodynamics

The primary cause of cardiovascular (CV) disease is atherosclerotic plaque formation and sustained elevation of cholesterol in the blood increases the risk of CV disease. Pravastatin lowers hepatic production of cholesterol by competitively inhibiting HMG-CoA reductase, the enzyme that catalyzes the rate-limiting step in the cholesterol biosynthesis pathway via the mevalonic acid pathway. Decreased hepatic cholesterol levels causes increased uptake of low density lipoprotein (LDL) cholesterol and reduces cholesterol levels in the circulation. Pravastatin also inhibits hepatic synthesis if VLDL. At therapeutic doses, pravastatin lowers LDL cholesterol by 20-30%, increase high density lipoprotein (HDL) cholesterol by 3-10%, and decrease plasma triglycerides by 19-34%. HDL cholesterol is thought to confer protective effects against CV disease, whereas high LDL and triglyceride levels are associated with higher risk of disease.

Mechanism of action

Pravastatin is structurally similar to the HMG, a substituent of the endogenous substrate of HMG-CoA reductase. Unlike its parent compound, mevastatin, and statins such as lovastatin and simvastatin, pravastatin does not need to be activated in vivo. Its hydrolyzed lactone ring mimics the tetrahedral intermediate produced by the reductase allowing the agent to bind with a much greater affinity than its natural substrate. The bicyclic portion of pravastatin binds to the coenzyme A portion of the active site. Pravastatin sodium produces its lipid-lowering effect in two ways. First, as a consequence of its reversible inhibition of HMG-CoA reductase activity, it effects modest reductions in intracellular pools of cholesterol. This results in an increase in the number of LDL-receptors on cell surfaces and enhanced receptor-mediated catabolism and clearance of circulating LDL. Second, pravastatin inhibits LDL production by inhibiting hepatic synthesis of VLDL, the LDL precursor.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Protein	yes	inhibitor	Human	P04035	details

Absorption

Pravastatin is rapidly absorbed with peak plasma levels of the parent compound achieved 1 to 1.5 hours after administration. The average oral absorption of pravastatin is 34% and absolute bioavailability is 17%. These values however, are variable. Food decreases the systemic bioavailability but the lipid-lowering effect is not impacted. When 20 mg of pravastatin is given orally, the pharmacokinetic parameters are as follows: Cmax = 23.3-26.3 ng/mL; AUC = 54.7 to 62.2 ng•hr/mL.

Volume of distribution

Not Available

Protein binding

50% bound to human plasma proteins.

Metabolism

Hepatic, there is a small amount of metabolism by P450 enzymes, but this effect is so minimal that inhibitory pharmacokinetic drug interactions have no real effect on its overall activity and elimination. An in vitro study which found moderate affinity for P450 2C9 (major), 2D6 and 3A4. Furthermore, the major degradation product is the 3α-hydroxy isomeric metabolite, which has one-tenth to one-fortieth the HMG-CoA reductase inhibitory activity of the parent compound.

Route of elimination

Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces. After intravenous administration, 47% of total body clearance was via renal excretion, while 53% was eliminated by non-renal routes.

Half life

77 hours

Clearance

Not Available

Toxicity

Side effects include diarrhea, nausea, constipation, gas abdominal pain, myopathy, myositis, rhabdomyolysis, and hepatotoxicity. LD₅₀= 12,000 mg/kg (orally in rat)

Affected organisms

Humans and other mammals

Pathways

Pathway	Category	SMPDB ID
Pravastatin Action Pathway	Drug action	SMP00089

Pharmacogenomic Effects/ADRs

Interacting Gene/Enzyme	Allele name	Genotype(s)	Defining Change(s)	Type(s)	Description	Details
Kinesin-like protein KIF6	---	(C;C) / (C;T)	C Allele	Effect Directly Studied	Improved response to statin drugs	Details
3-hydroxy-3-methylglutaryl-coenzyme A reductase	---	(A;T)	T Allele	Effect Directly Studied	Reduced response to statin drugs	Details

Interactions

Drug Interactions

Drug	Interaction	Drug group
Abiraterone	The metabolism of Pravastatin can be decreased when combined with Abiraterone.	Approved
Acebutolol	The serum concentration of Acebutolol can be increased when it is combined with Pravastatin.	Approved
Acenocoumarol	Pravastatin may increase the anticoagulant activities of Acenocoumarol.	Approved
Acetaminophen	The serum concentration of Pravastatin can be increased when it is combined with Acetaminophen.	Approved
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be increased when it is combined with Pravastatin.	Approved, Vet Approved
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Pravastatin.	Approved
Albendazole	The serum concentration of Pravastatin can be increased when it is combined with Albendazole.	Approved, Vet Approved
Aldosterone	The serum concentration of Pravastatin can be decreased when it is combined with Aldosterone.	Experimental
Alectinib	The serum concentration of Pravastatin can be increased when it is combined with Alectinib.	Approved
Alfentanil	The serum concentration of Pravastatin can be increased when it is combined with Alfentanil.	Approved, Illicit
Alitretinoin	The serum concentration of Alitretinoin can be increased when it is combined with Pravastatin.	Approved, Investigational
Aluminum hydroxide	The serum concentration of Pravastatin can be decreased when it is combined with Aluminum hydroxide.	Approved
Amantadine	The serum concentration of Pravastatin can be increased when it is combined with Amantadine.	Approved
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Pravastatin.	Approved, Investigational
Aminohippuric acid	The serum concentration of Pravastatin can be increased when it is combined with Aminohippuric acid.	Approved
Amiodarone	The metabolism of Pravastatin can be decreased when combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Pravastatin can be increased when it is combined with Amitriptyline.	Approved
Amlodipine	The serum concentration of Pravastatin can be increased when it is combined with Amlodipine.	Approved
Amodiaquine	The serum concentration of Amodiaquine can be increased when it is combined with Pravastatin.	Approved
Amprenavir	The serum concentration of Pravastatin can be decreased when it is combined with Amprenavir.	Approved
Amsacrine	The serum concentration of Pravastatin can be increased when it is combined with Amsacrine.	Approved
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Pravastatin.	Approved
Aprepitant	The serum concentration of Pravastatin can be increased when it is combined with Aprepitant.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be increased when it is combined with Pravastatin.	Approved, Investigational
Arsenic trioxide	The serum concentration of Arsenic trioxide can be increased when it is combined with Pravastatin.	Approved, Investigational
Astemizole	The serum concentration of Pravastatin can be increased when it is combined with Astemizole.	Approved, Withdrawn
Atazanavir	The metabolism of Pravastatin can be decreased when combined with Atazanavir.	Approved, Investigational
Atenolol	The serum concentration of Pravastatin can be increased when it is combined with Atenolol.	Approved
Atomoxetine	The metabolism of Pravastatin can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The serum concentration of Pravastatin can be increased when it is combined with Atorvastatin.	Approved
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Pravastatin.	Approved, Investigational
Azelastine	The serum concentration of Pravastatin can be increased when it is combined with Azelastine.	Approved
Azithromycin	The serum concentration of Pravastatin can be increased when it is combined with Azithromycin.	Approved
Benzocaine	The serum concentration of Pravastatin can be increased when it is combined with Benzocaine.	Approved
Bepridil	The serum concentration of Pravastatin can be increased when it is combined with Bepridil.	Approved, Withdrawn
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Pravastatin.	Approved, Vet Approved
Bexarotene	The serum concentration of Pravastatin can be decreased when it is combined with Bexarotene.	Approved, Investigational
Bezafibrate	Bezafibrate may increase the myopathic rhabdomyolysis activities of Pravastatin.	Approved
Biperiden	The serum concentration of Pravastatin can be increased when it is combined with Biperiden.	Approved
Bismuth Subcitrate	The serum concentration of Pravastatin can be decreased when it is combined with Bismuth Subcitrate.	Approved
Boceprevir	The serum concentration of Pravastatin can be increased when it is combined with Boceprevir.	Approved, Investigational
Bortezomib	The metabolism of Pravastatin can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The metabolism of Pravastatin can be increased when combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Pravastatin.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Pravastatin.	Approved
Bromocriptine	The serum concentration of Pravastatin can be increased when it is combined with Bromocriptine.	Approved, Investigational
Buprenorphine	The serum concentration of Pravastatin can be increased when it is combined with Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	The serum concentration of Pravastatin can be increased when it is combined with Buspirone.	Approved, Investigational
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Pravastatin.	Approved
Caffeine	The serum concentration of Pravastatin can be increased when it is combined with Caffeine.	Approved
Calcium Carbonate	The serum concentration of Pravastatin can be decreased when it is combined with Calcium carbonate.	Approved
Camptothecin	The serum concentration of Camptothecin can be increased when it is combined with Pravastatin.	Experimental
Canagliflozin	The serum concentration of Canagliflozin can be increased when it is combined with Pravastatin.	Approved
Candesartan	The serum concentration of Pravastatin can be increased when it is combined with Candesartan.	Approved
Capecitabine	The metabolism of Pravastatin can be decreased when combined with Capecitabine.	Approved, Investigational
Captopril	The serum concentration of Pravastatin can be increased when it is combined with Captopril.	Approved
Carbamazepine	The metabolism of Pravastatin can be increased when combined with Carbamazepine.	Approved, Investigational
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Pravastatin.	Approved
Carvedilol	The serum concentration of Pravastatin can be increased when it is combined with Carvedilol.	Approved, Investigational
Caspofungin	The serum concentration of Pravastatin can be increased when it is combined with Caspofungin.	Approved
Ceritinib	The serum concentration of Pravastatin can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Pravastatin.	Withdrawn
Chloroquine	The serum concentration of Pravastatin can be increased when it is combined with Chloroquine.	Approved, Vet Approved
Chlorpromazine	The serum concentration of Pravastatin can be increased when it is combined with Chlorpromazine.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Pravastatin can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Pravastatin can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Cholecalciferol	The metabolism of Pravastatin can be decreased when combined with Cholecalciferol.	Approved, Nutraceutical
Cholesterol	The serum concentration of Pravastatin can be increased when it is combined with Cholesterol.	Experimental
Cholestyramine	The serum concentration of Pravastatin can be decreased when it is combined with Cholestyramine.	Approved
Cholic Acid	The serum concentration of Pravastatin can be decreased when it is combined with Cholic Acid.	Approved
Cilazapril	The serum concentration of Pravastatin can be increased when it is combined with Cilazapril.	Approved
Cimetidine	The serum concentration of Pravastatin can be decreased when it is combined with Cimetidine.	Approved
Ciprofloxacin	The serum concentration of Pravastatin can be increased when it is combined with Ciprofloxacin.	Approved, Investigational
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Pravastatin.	Approved
Citalopram	The serum concentration of Pravastatin can be increased when it is combined with Citalopram.	Approved
Clarithromycin	The serum concentration of Pravastatin can be increased when it is combined with Clarithromycin.	Approved
Clemastine	The metabolism of Pravastatin can be decreased when combined with Clemastine.	Approved
Clobazam	The serum concentration of Clobazam can be increased when it is combined with Pravastatin.	Approved, Illicit
Clofazimine	The serum concentration of Pravastatin can be increased when it is combined with Clofazimine.	Approved, Investigational
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Pravastatin.	Approved, Investigational
Clomipramine	The serum concentration of Pravastatin can be increased when it is combined with Clomipramine.	Approved, Vet Approved
Clonidine	The serum concentration of Clonidine can be increased when it is combined with Pravastatin.	Approved
Clopidogrel	The serum concentration of Clopidogrel can be increased when it is combined with Pravastatin.	Approved, Nutraceutical
Clotrimazole	The metabolism of Pravastatin can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The serum concentration of Clozapine can be increased when it is combined with Pravastatin.	Approved
Cobicistat	The metabolism of Pravastatin can be decreased when combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Pravastatin.	Approved
Colchicine	Colchicine may increase the myopathic rhabdomyolysis activities of Pravastatin.	Approved
Colesevelam	The serum concentration of Pravastatin can be decreased when it is combined with Colesevelam.	Approved
Colestipol	The serum concentration of Pravastatin can be decreased when it is combined with Colestipol.	Approved
Colforsin	The serum concentration of Pravastatin can be increased when it is combined with Colforsin.	Experimental
Conivaptan	The serum concentration of Pravastatin can be increased when it is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Pravastatin.	Approved
Crizotinib	The metabolism of Pravastatin can be decreased when combined with Crizotinib.	Approved
Cyclophosphamide	The serum concentration of Pravastatin can be increased when it is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The serum concentration of Pravastatin can be increased when it is combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyclosporine	The metabolism of Pravastatin can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyproterone acetate	The serum concentration of Pravastatin can be increased when it is combined with Cyproterone acetate.	Approved, Investigational
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Pravastatin.	Approved
Dabrafenib	The serum concentration of Pravastatin can be decreased when it is combined with Dabrafenib.	Approved
Daclatasvir	The serum concentration of Pravastatin can be increased when it is combined with Daclatasvir.	Approved
Dactinomycin	The serum concentration of Pravastatin can be increased when it is combined with Dactinomycin.	Approved
Danazol	The serum concentration of Pravastatin can be increased when it is combined with Danazol.	Approved
Dapagliflozin	The serum concentration of Dapagliflozin can be increased when it is combined with Pravastatin.	Approved
Daptomycin	The risk or severity of adverse effects can be increased when Pravastatin is combined with Daptomycin.	Approved, Investigational
Darunavir	The serum concentration of Pravastatin can be increased when it is combined with Darunavir.	Approved
Dasatinib	The serum concentration of Pravastatin can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Pravastatin can be decreased when it is combined with Daunorubicin.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be increased when it is combined with Pravastatin.	Approved
Deferasirox	The serum concentration of Pravastatin can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Pravastatin can be decreased when combined with Delavirdine.	Approved
Desipramine	The serum concentration of Pravastatin can be increased when it is combined with Desipramine.	Approved
Desloratadine	The serum concentration of Pravastatin can be increased when it is combined with Desloratadine.	Approved, Investigational
Dexamethasone	The serum concentration of Pravastatin can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dextromethorphan	The serum concentration of Pravastatin can be increased when it is combined with Dextromethorphan.	Approved
Diazepam	The serum concentration of Diazepam can be increased when it is combined with Pravastatin.	Approved, Illicit, Vet Approved
Diclofenac	The serum concentration of Pravastatin can be increased when it is combined with Diclofenac.	Approved, Vet Approved
Dicoumarol	Pravastatin may increase the anticoagulant activities of Dicoumarol.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be increased when it is combined with Pravastatin.	Approved
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Pravastatin.	Approved
Digoxin	The serum concentration of Pravastatin can be decreased when it is combined with Digoxin.	Approved
Dihydroergotamine	The metabolism of Pravastatin can be decreased when combined with Dihydroergotamine.	Approved
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Pravastatin.	Illicit
Diltiazem	The metabolism of Pravastatin can be decreased when combined with Diltiazem.	Approved
Dipyridamole	The serum concentration of Pravastatin can be increased when it is combined with Dipyridamole.	Approved
Docetaxel	The serum concentration of Docetaxel can be increased when it is combined with Pravastatin.	Approved, Investigational
Domperidone	The serum concentration of Domperidone can be increased when it is combined with Pravastatin.	Approved, Investigational, Vet Approved
Doxazosin	The serum concentration of Pravastatin can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Pravastatin can be increased when it is combined with Doxepin.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Pravastatin.	Approved, Investigational
Doxorubicin	The serum concentration of Pravastatin can be decreased when it is combined with Doxorubicin.	Approved, Investigational
Doxycycline	The metabolism of Pravastatin can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronabinol	The serum concentration of Pravastatin can be increased when it is combined with Dronabinol.	Approved, Illicit
Dronedarone	The metabolism of Pravastatin can be decreased when combined with Dronedarone.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Pravastatin.	Approved
Efavirenz	The serum concentration of Pravastatin can be decreased when it is combined with Efavirenz.	Approved, Investigational
Elbasvir	The serum concentration of Pravastatin can be increased when it is combined with Elbasvir.	Approved
Eletriptan	The serum concentration of Eletriptan can be increased when it is combined with Pravastatin.	Approved, Investigational
Eltrombopag	The serum concentration of Pravastatin can be increased when it is combined with Eltrombopag.	Approved
Enalapril	The serum concentration of Pravastatin can be increased when it is combined with Enalapril.	Approved, Vet Approved
Enzalutamide	The serum concentration of Pravastatin can be decreased when it is combined with Enzalutamide.	Approved
Epinastine	The serum concentration of Epinastine can be increased when it is combined with Pravastatin.	Approved, Investigational
Ergonovine	The serum concentration of Pravastatin can be increased when it is combined with Ergonovine.	Approved
Ergotamine	The serum concentration of Pravastatin can be increased when it is combined with Ergotamine.	Approved
Erlotinib	The serum concentration of Erlotinib can be increased when it is combined with Pravastatin.	Approved, Investigational
Erythromycin	The metabolism of Pravastatin can be decreased when combined with Erythromycin.	Approved, Vet Approved
Erythromycin	The serum concentration of Pravastatin can be increased when it is combined with Erythromycin.	Approved, Vet Approved
Eslicarbazepine acetate	The serum concentration of Pravastatin can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Estradiol	The serum concentration of Estradiol can be increased when it is combined with Pravastatin.	Approved, Investigational, Vet Approved
Estramustine	The serum concentration of Pravastatin can be increased when it is combined with Estramustine.	Approved
Estriol	The serum concentration of Pravastatin can be decreased when it is combined with Estriol.	Approved, Vet Approved
Estrone	The serum concentration of Pravastatin can be decreased when it is combined with Estrone.	Approved
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be increased when it is combined with Pravastatin.	Approved
Ethyl biscoumacetate	Pravastatin may increase the anticoagulant activities of Ethyl biscoumacetate.	Withdrawn
Etoposide	The serum concentration of Pravastatin can be increased when it is combined with Etoposide.	Approved
Etravirine	The serum concentration of Pravastatin can be decreased when it is combined with Etravirine.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Pravastatin.	Approved
Ezetimibe	The serum concentration of Ezetimibe can be increased when it is combined with Pravastatin.	Approved
Felodipine	The serum concentration of Pravastatin can be increased when it is combined with Felodipine.	Approved, Investigational
Fenofibrate	The risk or severity of adverse effects can be increased when Fenofibrate is combined with Pravastatin.	Approved
Fentanyl	The serum concentration of Pravastatin can be increased when it is combined with Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Pravastatin.	Approved
Fexofenadine	The serum concentration of Pravastatin can be increased when it is combined with Fexofenadine.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be increased when it is combined with Pravastatin.	Approved
Floxuridine	The metabolism of Pravastatin can be decreased when combined with Floxuridine.	Approved
Fluconazole	The metabolism of Pravastatin can be decreased when combined with Fluconazole.	Approved
Fluindione	Pravastatin may increase the anticoagulant activities of Fluindione.	Investigational
Fluorouracil	The metabolism of Pravastatin can be decreased when combined with Fluorouracil.	Approved
Fluoxetine	The serum concentration of Pravastatin can be increased when it is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	The serum concentration of Pravastatin can be increased when it is combined with Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Pravastatin can be increased when it is combined with Fluphenazine.	Approved
Flurazepam	The serum concentration of Pravastatin can be increased when it is combined with Flurazepam.	Approved, Illicit
Fluticasone furoate	The serum concentration of Fluticasone furoate can be increased when it is combined with Pravastatin.	Approved
Fluvastatin	The metabolism of Pravastatin can be decreased when combined with Fluvastatin.	Approved
Fluvoxamine	The metabolism of Pravastatin can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Pravastatin can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Pravastatin can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of Pravastatin can be decreased when it is combined with Fosphenytoin.	Approved
Fusidic Acid	The serum concentration of Pravastatin can be increased when it is combined with Fusidic Acid.	Approved
Gefitinib	The serum concentration of Gefitinib can be increased when it is combined with Pravastatin.	Approved, Investigational
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Pravastatin.	Approved
Gemfibrozil	Gemfibrozil may increase the myopathic rhabdomyolysis activities of Pravastatin.	Approved
Genistein	The serum concentration of Pravastatin can be increased when it is combined with Genistein.	Investigational
Glyburide	The serum concentration of Pravastatin can be increased when it is combined with Glyburide.	Approved
Gramicidin D	The serum concentration of Pravastatin can be increased when it is combined with Gramicidin D.	Approved
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Pravastatin.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be increased when it is combined with Pravastatin.	Withdrawn
Haloperidol	The serum concentration of Pravastatin can be increased when it is combined with Haloperidol.	Approved
Hydrocortisone	The serum concentration of Pravastatin can be increased when it is combined with Hydrocortisone.	Approved, Vet Approved
Ibuprofen	The serum concentration of Ibuprofen can be increased when it is combined with Pravastatin.	Approved
Idelalisib	The serum concentration of Pravastatin can be increased when it is combined with Idelalisib.	Approved
Imatinib	The metabolism of Pravastatin can be decreased when combined with Imatinib.	Approved
Imipramine	The serum concentration of Pravastatin can be increased when it is combined with Imipramine.	Approved
Indacaterol	The serum concentration of Indacaterol can be increased when it is combined with Pravastatin.	Approved
Indinavir	The metabolism of Pravastatin can be decreased when combined with Indinavir.	Approved
Indomethacin	The serum concentration of Pravastatin can be increased when it is combined with Indomethacin.	Approved, Investigational
Irbesartan	The metabolism of Pravastatin can be decreased when combined with Irbesartan.	Approved, Investigational
Irinotecan	The serum concentration of Irinotecan can be increased when it is combined with Pravastatin.	Approved, Investigational
Isavuconazonium	The metabolism of Pravastatin can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isradipine	The metabolism of Pravastatin can be decreased when combined with Isradipine.	Approved
Itraconazole	The serum concentration of Pravastatin can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Pravastatin can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Pravastatin can be increased when it is combined with Ivermectin.	Approved, Vet Approved
Ketamine	The serum concentration of Pravastatin can be increased when it is combined with Ketamine.	Approved, Vet Approved
Ketazolam	The serum concentration of Ketazolam can be increased when it is combined with Pravastatin.	Approved
Ketoconazole	The metabolism of Pravastatin can be decreased when combined with Ketoconazole.	Approved, Investigational
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Pravastatin.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be increased when it is combined with Pravastatin.	Approved, Investigational
Lansoprazole	The serum concentration of Pravastatin can be increased when it is combined with Lansoprazole.	Approved, Investigational
Lanthanum carbonate	The serum concentration of Lanthanum carbonate can be decreased when it is combined with Pravastatin.	Approved
Lapatinib	The serum concentration of Pravastatin can be increased when it is combined with Lapatinib.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Pravastatin.	Approved
Leflunomide	The metabolism of Pravastatin can be decreased when combined with Leflunomide.	Approved, Investigational
Lenalidomide	The serum concentration of Lenalidomide can be increased when it is combined with Pravastatin.	Approved
Lenvatinib	The serum concentration of Lenvatinib can be increased when it is combined with Pravastatin.	Approved
Levetiracetam	The serum concentration of Levetiracetam can be increased when it is combined with Pravastatin.	Approved, Investigational
Levofloxacin	The serum concentration of Pravastatin can be increased when it is combined with Levofloxacin.	Approved, Investigational
Levomilnacipran	The serum concentration of Levomilnacipran can be increased when it is combined with Pravastatin.	Approved
Levothyroxine	The serum concentration of Pravastatin can be decreased when it is combined with Levothyroxine.	Approved
Lidocaine	The serum concentration of Pravastatin can be increased when it is combined with Lidocaine.	Approved, Vet Approved
Linagliptin	The serum concentration of Linagliptin can be increased when it is combined with Pravastatin.	Approved
Liothyronine	The serum concentration of Pravastatin can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Pravastatin can be decreased when it is combined with Liotrix.	Approved
Lisinopril	The serum concentration of Pravastatin can be increased when it is combined with Lisinopril.	Approved, Investigational
Lomitapide	The serum concentration of Pravastatin can be increased when it is combined with Lomitapide.	Approved
Loperamide	The serum concentration of Pravastatin can be increased when it is combined with Loperamide.	Approved
Lopinavir	The metabolism of Pravastatin can be decreased when combined with Lopinavir.	Approved
Loratadine	The serum concentration of Pravastatin can be increased when it is combined with Loratadine.	Approved
Losartan	The serum concentration of Pravastatin can be increased when it is combined with Losartan.	Approved
Lovastatin	The metabolism of Pravastatin can be decreased when combined with Lovastatin.	Approved, Investigational
Luliconazole	The serum concentration of Pravastatin can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Pravastatin can be decreased when it is combined with Lumacaftor.	Approved
Magaldrate	The serum concentration of Pravastatin can be decreased when it is combined with Magaldrate.	Withdrawn
Magnesium carbonate	The serum concentration of Pravastatin can be decreased when it is combined with Magnesium carbonate.	Approved
Magnesium Hydroxide	The serum concentration of Pravastatin can be decreased when it is combined with Magnesium hydroxide.	Approved
Magnesium oxide	The serum concentration of Pravastatin can be decreased when it is combined with Magnesium oxide.	Approved
Magnesium Trisilicate	The serum concentration of Pravastatin can be decreased when it is combined with Magnesium Trisilicate.	Approved
Mannitol	The serum concentration of Mannitol can be increased when it is combined with Pravastatin.	Approved, Investigational
Maprotiline	The serum concentration of Pravastatin can be increased when it is combined with Maprotiline.	Approved
Mebendazole	The serum concentration of Pravastatin can be increased when it is combined with Mebendazole.	Approved, Vet Approved
Mefloquine	The serum concentration of Pravastatin can be increased when it is combined with Mefloquine.	Approved
Megestrol acetate	The serum concentration of Pravastatin can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Meprobamate	The serum concentration of Pravastatin can be increased when it is combined with Meprobamate.	Approved, Illicit
Methadone	The serum concentration of Pravastatin can be increased when it is combined with Methadone.	Approved
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Pravastatin.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be increased when it is combined with Pravastatin.	Approved, Vet Approved
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Pravastatin.	Approved, Investigational
Mibefradil	The serum concentration of Pravastatin can be increased when it is combined with Mibefradil.	Withdrawn
Miconazole	The serum concentration of Pravastatin can be increased when it is combined with Miconazole.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Pravastatin can be decreased when it is combined with Midazolam.	Approved, Illicit
Mifepristone	The serum concentration of Pravastatin can be increased when it is combined with Mifepristone.	Approved, Investigational
Mirabegron	The serum concentration of Mirabegron can be increased when it is combined with Pravastatin.	Approved
Mitomycin	The serum concentration of Pravastatin can be increased when it is combined with Mitomycin.	Approved
Mitotane	The serum concentration of Pravastatin can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Pravastatin can be decreased when it is combined with Mitoxantrone.	Approved, Investigational
Modafinil	The serum concentration of Pravastatin can be decreased when it is combined with Modafinil.	Approved, Investigational
Morphine	The serum concentration of Pravastatin can be increased when it is combined with Morphine.	Approved, Investigational
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be increased when it is combined with Pravastatin.	Approved, Investigational
Nadolol	The serum concentration of Nadolol can be increased when it is combined with Pravastatin.	Approved
Nafcillin	The serum concentration of Pravastatin can be decreased when it is combined with Nafcillin.	Approved
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Pravastatin.	Approved
Naloxone	The serum concentration of Naloxone can be increased when it is combined with Pravastatin.	Approved, Vet Approved
Naltrexone	The serum concentration of Pravastatin can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naringenin	The serum concentration of Pravastatin can be increased when it is combined with Naringenin.	Experimental
Nefazodone	The metabolism of Pravastatin can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The serum concentration of Pravastatin can be decreased when it is combined with Nelfinavir.	Approved
Neostigmine	The serum concentration of Pravastatin can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Netupitant	The serum concentration of Pravastatin can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Pravastatin can be increased when combined with Nevirapine.	Approved
Niacin	The risk or severity of adverse effects can be increased when Niacin is combined with Pravastatin.	Approved, Investigational, Nutraceutical
Nicardipine	The metabolism of Pravastatin can be decreased when combined with Nicardipine.	Approved
Nicotinamide	The risk or severity of adverse effects can be increased when Nicotinamide is combined with Pravastatin.	Approved
Nifedipine	The serum concentration of Pravastatin can be decreased when it is combined with Nifedipine.	Approved
Nilotinib	The metabolism of Pravastatin can be decreased when combined with Nilotinib.	Approved, Investigational
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Pravastatin.	Approved
Nisoldipine	The serum concentration of Pravastatin can be increased when it is combined with Nisoldipine.	Approved
Nitrazepam	The serum concentration of Pravastatin can be increased when it is combined with Nitrazepam.	Approved
Nitrendipine	The serum concentration of Pravastatin can be increased when it is combined with Nitrendipine.	Approved
Nizatidine	The serum concentration of Nizatidine can be increased when it is combined with Pravastatin.	Approved
Norethisterone	The serum concentration of Pravastatin can be decreased when it is combined with Norethisterone.	Approved
Olanzapine	The serum concentration of Olanzapine can be increased when it is combined with Pravastatin.	Approved, Investigational
Olaparib	The metabolism of Pravastatin can be decreased when combined with Olaparib.	Approved
Ombitasvir	The serum concentration of Ombitasvir can be increased when it is combined with Pravastatin.	Approved
Omeprazole	The serum concentration of Pravastatin can be increased when it is combined with Omeprazole.	Approved, Investigational, Vet Approved
Osimertinib	The serum concentration of Pravastatin can be increased when it is combined with Osimertinib.	Approved
P-Nitrophenol	The serum concentration of Pravastatin can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The serum concentration of Pravastatin can be increased when it is combined with Paclitaxel.	Approved, Vet Approved
Palbociclib	The serum concentration of Pravastatin can be increased when it is combined with Palbociclib.	Approved
Palmitic Acid	The serum concentration of Pravastatin can be increased when it is combined with Palmitic Acid.	Experimental
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Pravastatin.	Approved, Investigational
Pantoprazole	The serum concentration of Pravastatin can be increased when it is combined with Pantoprazole.	Approved
Paroxetine	The risk or severity of adverse effects can be increased when Pravastatin is combined with Paroxetine.	Approved, Investigational
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Pravastatin.	Approved
Pentobarbital	The metabolism of Pravastatin can be increased when combined with Pentobarbital.	Approved, Vet Approved
Perindopril	The serum concentration of Pravastatin can be increased when it is combined with Perindopril.	Approved
Phenindione	Pravastatin may increase the anticoagulant activities of Phenindione.	Approved
Phenobarbital	The metabolism of Pravastatin can be increased when combined with Phenobarbital.	Approved
Phenprocoumon	Pravastatin may increase the anticoagulant activities of Phenprocoumon.	Approved
Phenytoin	The serum concentration of Pravastatin can be decreased when it is combined with Phenytoin.	Approved, Vet Approved
Pimozide	The serum concentration of Pravastatin can be increased when it is combined with Pimozide.	Approved
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Pravastatin.	Approved
Platelet Activating Factor	The serum concentration of Pravastatin can be decreased when it is combined with Platelet Activating Factor.	Experimental
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Pravastatin.	Approved
Ponatinib	The serum concentration of Ponatinib can be increased when it is combined with Pravastatin.	Approved
Posaconazole	The metabolism of Pravastatin can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Prazosin	The serum concentration of Pravastatin can be increased when it is combined with Prazosin.	Approved
Prednisolone	The serum concentration of Prednisolone can be increased when it is combined with Pravastatin.	Approved, Vet Approved
Prednisone	The serum concentration of Pravastatin can be increased when it is combined with Prednisone.	Approved, Vet Approved
Primidone	The metabolism of Pravastatin can be increased when combined with Primidone.	Approved, Vet Approved
Probenecid	The serum concentration of Pravastatin can be increased when it is combined with Probenecid.	Approved
Progesterone	The serum concentration of Pravastatin can be decreased when it is combined with Progesterone.	Approved, Vet Approved
Promethazine	The serum concentration of Pravastatin can be increased when it is combined with Promethazine.	Approved
Propafenone	The serum concentration of Pravastatin can be increased when it is combined with Propafenone.	Approved
Propranolol	The serum concentration of Pravastatin can be increased when it is combined with Propranolol.	Approved, Investigational
Protriptyline	The serum concentration of Pravastatin can be increased when it is combined with Protriptyline.	Approved
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Pravastatin.	Approved
Pyrimethamine	The metabolism of Pravastatin can be decreased when combined with Pyrimethamine.	Approved, Vet Approved
Quercetin	The serum concentration of Pravastatin can be increased when it is combined with Quercetin.	Experimental
Quetiapine	The serum concentration of Quetiapine can be increased when it is combined with Pravastatin.	Approved
Quinacrine	The serum concentration of Pravastatin can be increased when it is combined with Quinacrine.	Approved
Quinidine	The serum concentration of Pravastatin can be increased when it is combined with Quinidine.	Approved
Quinine	The serum concentration of Pravastatin can be increased when it is combined with Quinine.	Approved
Raltegravir	Raltegravir may increase the myopathic rhabdomyolysis activities of Pravastatin.	Approved
Ranitidine	The serum concentration of Pravastatin can be increased when it is combined with Ranitidine.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Pravastatin.	Approved, Investigational
Reboxetine	The serum concentration of Pravastatin can be increased when it is combined with Reboxetine.	Approved, Investigational
Regorafenib	The serum concentration of Pravastatin can be increased when it is combined with Regorafenib.	Approved
Reserpine	The serum concentration of Pravastatin can be decreased when it is combined with Reserpine.	Approved
Rifabutin	The metabolism of Pravastatin can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Pravastatin can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Pravastatin can be increased when combined with Rifapentine.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Pravastatin.	Approved, Investigational
Rilpivirine	The serum concentration of Pravastatin can be increased when it is combined with Rilpivirine.	Approved
Risperidone	The serum concentration of Risperidone can be increased when it is combined with Pravastatin.	Approved, Investigational
Ritonavir	The metabolism of Pravastatin can be decreased when combined with Ritonavir.	Approved, Investigational
Rivaroxaban	The serum concentration of Rivaroxaban can be increased when it is combined with Pravastatin.	Approved
Rolapitant	The serum concentration of Pravastatin can be increased when it is combined with Rolapitant.	Approved
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Pravastatin.	Approved, Investigational
Salicylic acid	The serum concentration of Salicylic acid can be increased when it is combined with Pravastatin.	Approved, Vet Approved
Saquinavir	The serum concentration of Pravastatin can be decreased when it is combined with Saquinavir.	Approved, Investigational
Scopolamine	The serum concentration of Pravastatin can be increased when it is combined with Scopolamine.	Approved
Secobarbital	The metabolism of Pravastatin can be increased when combined with Secobarbital.	Approved, Vet Approved
Selegiline	The serum concentration of Pravastatin can be increased when it is combined with Selegiline.	Approved, Investigational, Vet Approved
Selexipag	The serum concentration of Selexipag can be increased when it is combined with Pravastatin.	Approved
Sertraline	The serum concentration of Pravastatin can be increased when it is combined with Sertraline.	Approved
Sildenafil	The metabolism of Pravastatin can be decreased when combined with Sildenafil.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Pravastatin.	Approved
Siltuximab	The serum concentration of Pravastatin can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Pravastatin can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The serum concentration of Pravastatin can be increased when it is combined with Simvastatin.	Approved
Sirolimus	The serum concentration of Pravastatin can be decreased when it is combined with Sirolimus.	Approved, Investigational
Sitagliptin	The serum concentration of Sitagliptin can be increased when it is combined with Pravastatin.	Approved, Investigational
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Pravastatin.	Approved
Sorafenib	The serum concentration of Sorafenib can be increased when it is combined with Pravastatin.	Approved, Investigational
Sparfloxacin	The serum concentration of Sparfloxacin can be increased when it is combined with Pravastatin.	Approved
Sphingosine	The serum concentration of Sphingosine can be increased when it is combined with Pravastatin.	Experimental
Spironolactone	The serum concentration of Pravastatin can be increased when it is combined with Spironolactone.	Approved
St. John's Wort	The metabolism of Pravastatin can be increased when combined with St. John's Wort.	Nutraceutical
Staurosporine	The serum concentration of Pravastatin can be increased when it is combined with Staurosporine.	Experimental
Stiripentol	The serum concentration of Pravastatin can be increased when it is combined with Stiripentol.	Approved
Streptozocin	The serum concentration of Pravastatin can be decreased when it is combined with Streptozocin.	Approved
Sulfadiazine	The metabolism of Pravastatin can be decreased when combined with Sulfadiazine.	Approved, Vet Approved
Sulfamethoxazole	The metabolism of Pravastatin can be decreased when combined with Sulfamethoxazole.	Approved
Sulfinpyrazone	The serum concentration of Pravastatin can be increased when it is combined with Sulfinpyrazone.	Approved
Sulfisoxazole	The metabolism of Pravastatin can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Sumatriptan	The serum concentration of Pravastatin can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The serum concentration of Pravastatin can be increased when it is combined with Sunitinib.	Approved, Investigational
Tacrine	The serum concentration of Pravastatin can be increased when it is combined with Tacrine.	Withdrawn
Tacrolimus	The serum concentration of Pravastatin can be decreased when it is combined with Tacrolimus.	Approved, Investigational
Tamoxifen	The serum concentration of Pravastatin can be decreased when it is combined with Tamoxifen.	Approved
Taurocholic Acid	The serum concentration of Pravastatin can be increased when it is combined with Taurocholic Acid.	Experimental
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Pravastatin.	Approved
Telaprevir	The serum concentration of Pravastatin can be increased when it is combined with Telaprevir.	Withdrawn
Telithromycin	The serum concentration of Pravastatin can be increased when it is combined with Telithromycin.	Approved
Telmisartan	The serum concentration of Pravastatin can be increased when it is combined with Telmisartan.	Approved, Investigational
Temsirolimus	The serum concentration of Temsirolimus can be increased when it is combined with Pravastatin.	Approved
Terazosin	The serum concentration of Pravastatin can be increased when it is combined with Terazosin.	Approved
Terfenadine	The serum concentration of Pravastatin can be increased when it is combined with Terfenadine.	Withdrawn
Teriflunomide	The serum concentration of Pravastatin can be increased when it is combined with Teriflunomide.	Approved
Tesmilifene	The serum concentration of Pravastatin can be decreased when it is combined with Tesmilifene.	Investigational
Testosterone	The serum concentration of Pravastatin can be increased when it is combined with Testosterone.	Approved, Investigational
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Pravastatin.	Withdrawn
Ticagrelor	The serum concentration of Ticagrelor can be increased when it is combined with Pravastatin.	Approved
Ticlopidine	The metabolism of Pravastatin can be decreased when combined with Ticlopidine.	Approved
Timolol	The serum concentration of Timolol can be increased when it is combined with Pravastatin.	Approved
Tocilizumab	The serum concentration of Pravastatin can be decreased when it is combined with Tocilizumab.	Approved
Tolbutamide	The metabolism of Pravastatin can be decreased when combined with Tolbutamide.	Approved
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Pravastatin.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Pravastatin.	Approved, Investigational
Toremifene	The serum concentration of Toremifene can be increased when it is combined with Pravastatin.	Approved, Investigational
Trabectedin	Pravastatin may increase the myopathic rhabdomyolysis activities of Trabectedin.	Approved, Investigational
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Pravastatin.	Approved
Trazodone	The serum concentration of Pravastatin can be decreased when it is combined with Trazodone.	Approved, Investigational
Trifluoperazine	The serum concentration of Pravastatin can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Pravastatin can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimethoprim	The serum concentration of Pravastatin can be decreased when it is combined with Trimethoprim.	Approved, Vet Approved
Trimipramine	The serum concentration of Pravastatin can be increased when it is combined with Trimipramine.	Approved
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Pravastatin.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Pravastatin.	Approved
Valproic Acid	The metabolism of Pravastatin can be decreased when combined with Valproic Acid.	Approved, Investigational
Valsartan	The metabolism of Pravastatin can be decreased when combined with Valsartan.	Approved, Investigational
Vecuronium	The serum concentration of Vecuronium can be increased when it is combined with Pravastatin.	Approved
Venetoclax	The serum concentration of Venetoclax can be increased when it is combined with Pravastatin.	Approved
Venlafaxine	The metabolism of Pravastatin can be decreased when combined with Venlafaxine.	Approved
Verapamil	The metabolism of Pravastatin can be decreased when combined with Verapamil.	Approved
Vinblastine	The serum concentration of Pravastatin can be decreased when it is combined with Vinblastine.	Approved
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Pravastatin.	Approved, Investigational
Vincristine	The serum concentration of Pravastatin can be decreased when it is combined with Vincristine.	Approved, Investigational
Vinorelbine	The serum concentration of Pravastatin can be increased when it is combined with Vinorelbine.	Approved, Investigational
Vismodegib	The serum concentration of Vismodegib can be increased when it is combined with Pravastatin.	Approved
Voriconazole	The metabolism of Pravastatin can be decreased when combined with Voriconazole.	Approved, Investigational
Warfarin	Pravastatin may increase the anticoagulant activities of Warfarin.	Approved
Zafirlukast	The metabolism of Pravastatin can be decreased when combined with Zafirlukast.	Approved, Investigational
Zidovudine	The serum concentration of Zidovudine can be increased when it is combined with Pravastatin.	Approved
Zimelidine	The serum concentration of Pravastatin can be increased when it is combined with Zimelidine.	Withdrawn
Ziprasidone	The metabolism of Pravastatin can be decreased when combined with Ziprasidone.	Approved

Food Interactions

Avoid alcohol.
Avoid drastic changes in dietary habit.
Take without regard to meals.

References

Synthesis Reference

Kae Jong Chung, Joo Kyung Lee, Joo Woong Park, Dong Jin Seo, Sang Choon Lee, "Method for producing pravastatin precursor, ML-236B." U.S. Patent US6204032, issued October, 1976.

US6204032

General References

Not Available

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB05022
KEGG Drug	D00893
KEGG Compound	C01844
PubChem Compound	54687
PubChem Substance	46504851
ChemSpider	49398
BindingDB	20688
ChEBI	63618
ChEMBL	CHEMBL1144
Therapeutic Targets Database	DAP000550
PharmGKB	PA451089
Drug Product Database	1201
RxList	http://www.rxlist.com/cgi/generic/pravast.htm
Drugs.com	http://www.drugs.com/cdi/pravastatin.html
Wikipedia	Pravastatin

ATC Codes

C10AA03 — Pravastatin

C10BX02 — Pravastatin and acetylsalicylic acid

C10BA03 — Pravastatin and fenofibrate

AHFS Codes

24:06.08

PDB Entries

Not Available

FDA label

Download (145 KB)

MSDS

Download (44 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Completed	Prevention	Ventilator-associated Bacterial Pneumonia	1
1	Active Not Recruiting	Prevention	Glomerulonephritis minimal lesion / Hyperlipidemias	1
1	Completed	Not Available	Healthy Volunteers	4
1	Completed	Basic Science	Cancer, Breast	1
1	Completed	Basic Science	Drug Biotransformation / Membrane Transport	1
1	Completed	Basic Science	Drug Interactions	1
1	Completed	Basic Science	Genotype-related Drug Metabolism	1
1	Completed	Basic Science	Healthy Volunteers	3
1	Completed	Basic Science	Rheumatoid Arthritis	1
1	Completed	Treatment	Acute Kidney Injury (AKI)	1
1	Completed	Treatment	HIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies	1
1	Completed	Treatment	Healthy Volunteers	4
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	3
1	Completed	Treatment	Leukemias	1
1	Completed	Treatment	Therapeutic Equivalency	2
1	Recruiting	Not Available	Healthy Volunteers	1
1	Recruiting	Prevention	PreEclampsia	1
1	Recruiting	Treatment	Drug Distribution	1
1	Recruiting	Treatment	Dyslipidemias / Peripheral Artery Disease (PAD)	1
1	Recruiting	Treatment	Leukemias	1
1, 2	Terminated	Treatment	Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia	1
1, 2	Terminated	Treatment	Albinism, Oculocutaneous / Hermansky-Pudlak Syndrome (HPS) / Metabolic Diseases / Platelet Storage Pool Deficiency / Pulmonary Fibrosis	1
2	Active Not Recruiting	Treatment	CHILD B / Hepatocellular,Carcinoma	1
2	Active Not Recruiting	Treatment	Progeria	1
2	Completed	Treatment	Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Heart Diseases / Myocardial Ischemia	1
2	Completed	Treatment	Diabetes Mellitus (DM) / Hypercholesterolaemia / Metabolic Syndromes	1
2	Completed	Treatment	Dyslipidemias	1
2	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Hypercholesterolaemia	1
2	Completed	Treatment	Hypercholesterolaemia / Statin-Associated Myopathy	1
2	Completed	Treatment	Hypercholesterolemia, Familial	1
2	Completed	Treatment	Lupus / Systemic Lupus Erythematosus (SLE)	1
2	Completed	Treatment	Progeria	1
2	Not Yet Recruiting	Treatment	Coronary Heart Disease (CHD) / Human Immunodeficiency Virus (HIV) Infections	1
2	Recruiting	Treatment	Fibrosis	1
2	Recruiting	Treatment	Leukemias	1
2	Unknown Status	Treatment	Advanced Hepatocarcinoma	1
2	Withdrawn	Treatment	HIV-1 Infections	1
2	Withdrawn	Treatment	Mucocutaneous Lymph Node Syndrome	1
3	Completed	Basic Science	Hypercholesterolaemia / Hyperlipoproteinemias	1
3	Completed	Prevention	Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Heart Failure, Unspecified / Hypercholesterolaemia / Hypertensive / Myocardial Infarction (MI) / Myocardial Ischemia	1
3	Completed	Prevention	Cardiovascular Disease (CVD) / Microalbuminuria / Renal Diseases	1
3	Completed	Prevention	Stroke, Ischemic	1
3	Completed	Treatment	Arterial Occlusive Diseases / Cardiovascular Disease (CVD) / Diabetes Mellitus (DM) / Heart Diseases / Vascular Diseases	1
3	Completed	Treatment	Atherosclerosis / Cardiovascular Disease (CVD)	1
3	Completed	Treatment	Child-Pugh A Hepatocellular Carcinoma	1
3	Completed	Treatment	Chronic Allograft Nephropathy (CAN) / End-Stage Renal Disease (ESRD)	1
3	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies	1
3	Completed	Treatment	Hypercholesterolaemia	2
3	Completed	Treatment	Hypercholesterolemia or Combined Dyslipidemia	1
3	Completed	Treatment	Hyperlipidemias	1
3	Completed	Treatment	Hyperlipoproteinemia Type III	1
3	Completed	Treatment	Liver Cancer	1
3	Completed	Treatment	Lung Cancers	1
3	Completed	Treatment	Polycystic Kidney, Autosomal Dominant	1
3	Completed	Treatment	Relapsing Remitting Multiple Sclerosis (RRMS)	1
3	Terminated	Treatment	Hypercholesterolaemia	1
3	Terminated	Treatment	Hypertensive	1
4	Completed	Prevention	Actue Coronary Syndromes	1
4	Completed	Prevention	Aging / Alzheimer's Disease (AD)	1
4	Completed	Prevention	Cardiovascular Disease (CVD)	1
4	Completed	Prevention	Hyperlipidemias	1
4	Completed	Treatment	Acute Coronary Syndromes (ACS)	1
4	Completed	Treatment	Cardiovascular Disease (CVD) / Glucose Metabolism / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies / Metabolic Abnormality / Metabolism, Lipids	1
4	Completed	Treatment	Chronic Heart Failure (CHF)	1
4	Completed	Treatment	Coronary Arteriosclerosis	1
4	Completed	Treatment	Coronary Heart Disease (CHD) / Hypercholesterolaemia	1
4	Completed	Treatment	Dyslipidemias	2
4	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Hyperlipidemias	2
4	Completed	Treatment	Hypercholesterolaemia	2
4	Completed	Treatment	Hypertriglycemia / Type 2 Diabetes Mellitus	1
4	Completed	Treatment	Multi-vessel Diseases, Angina	1
4	Completed	Treatment	Chronic, stable Angina pectoris / Non ST Segment Elevation Myocardial Infarction (NSTEMI) / Unstable Angina Pectoris	1
4	Completed	Treatment	Mixed hypercholesterolemia / Primary Dyslipidemia	1
4	Completed	Treatment	Schizoaffective Disorders / Schizophrenic Disorders	1
4	Completed	Treatment	Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorders	1
4	Completed	Treatment	Type IIa and IIb Hypercholesterolaemia	1
4	Recruiting	Health Services Research	Diabetes	1
4	Recruiting	Prevention	Hypertensive / Strokes / Transient Ischaemic Attack (TIA)	1
4	Recruiting	Treatment	Chronic Kidney Disease (CKD)	1
4	Recruiting	Treatment	Coronary Artery Disease	1
4	Recruiting	Treatment	Diabetes Mellitus (DM) / Prediabetic State	1
4	Terminated	Not Available	Statin Adverse Reaction / Statin-Associated Myopathy	1
4	Terminated	Treatment	Chronic Kidney Disease (CKD)	1
4	Terminated	Treatment	Heart Failure, Unspecified	1
4	Unknown Status	Prevention	Acute Myocardial Infarction (AMI)	1
4	Unknown Status	Treatment	Coronary Heart Disease (CHD) / Hypercholesterolaemia	1
4	Unknown Status	Treatment	Drug-eluting Stent (DES)	1
4	Unknown Status	Treatment	Esophageal Cancers / Malignant Neoplasm of Stomach	1
4	Unknown Status	Treatment	HIV Disease / Human Immunodeficiency Virus (HIV) Infections / Hyperlipidemias	1
Not Available	Completed	Not Available	Cardiovascular Disease (CVD) / Type 2 Diabetes Mellitus	1
Not Available	Completed	Not Available	Hypercholesterolaemia	3
Not Available	Completed	Not Available	Pediatrics Patients on Dialysis	1
Not Available	Completed	Not Available	Postpartum Depression	1
Not Available	Completed	Prevention	Cardiovascular Disease Risk / Human Immunodeficiency Virus (HIV) Infections	1
Not Available	Completed	Treatment	Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Refractory Anemia With Excess Blasts / Untreated Adult Acute Myeloid Leukemia	1
Not Available	Completed	Treatment	Coronary Artery Disease	1
Not Available	Not Yet Recruiting	Treatment	Endometriosis	1
Not Available	Recruiting	Treatment	Coronary Artery Occlusive Disease	1
Not Available	Suspended	Prevention	Traumatic Brain Injury (TBI)	1
Not Available	Terminated	Prevention	Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus	1
Not Available	Terminated	Treatment	Metabolic Syndromes	1
Not Available	Unknown Status	Screening	Dyslipidemias	1
Not Available	Unknown Status	Treatment	Crohn's Disease (CD)	1
Not Available	Unknown Status	Treatment	Heart Diseases	1
Not Available	Withdrawn	Treatment	Endometriosis	1

Pharmacoeconomics

Manufacturers

Bristol myers squibb
Apotex corp
Dr reddys laboratories inc
Glenmark generics ltd
Lek pharmaceuticals dd
Lupin pharmaceuticals inc
Matrix laboratories ltd
Mylan pharmaceuticals inc
Pliva hrvatska doo
Ranbaxy laboratories ltd
Teva pharmaceuticals usa inc
Teva pharmaceuticals usa
Watson laboratories inc
Zydus pharmaceuticals usa inc

Packagers

Advanced Pharmaceutical Services Inc.
Amerisource Health Services Corp.
Apotex Inc.
A-S Medication Solutions LLC
Bristol-Myers Squibb Co.
Bryant Ranch Prepack
Cadila Healthcare Ltd.
Cardinal Health
Cobalt Pharmaceuticals Inc.
Comprehensive Consultant Services Inc.
Dept Health Central Pharmacy
Dispensing Solutions
Diversified Healthcare Services Inc.
Doctor Reddys Laboratories Ltd.
E.R. Squibb and Sons LLC
Glenmark Generics Ltd.
International Laboratories Inc.
Kaiser Foundation Hospital
Lek Pharmaceuticals Inc.
Lupin Pharmaceuticals Inc.
Major Pharmaceuticals
Medvantx Inc.
Murfreesboro Pharmaceutical Nursing Supply
Mylan
Neuman Distributors Inc.
Ohm Laboratories Inc.
Palmetto Pharmaceuticals Inc.
Par Pharmaceuticals
PD-Rx Pharmaceuticals Inc.
Pharmaceutical Utilization Management Program VA Inc.
Physicians Total Care Inc.
Pliva Inc.
Prepackage Specialists
Prepak Systems Inc.
Ranbaxy Laboratories
Rebel Distributors Corp.
Resource Optimization and Innovation LLC
Sandoz
Southwood Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
UDL Laboratories
Vangard Labs Inc.
Zydus Pharmaceuticals

Dosage forms

Form	Route	Strength
Tablet	Oral	10 mg
Kit; tablet; tablet, delayed release	Oral
Tablet	Oral	80 mg
Tablet	Oral	20 mg
Tablet	Oral	40 mg
Tablet	Oral	80 mg/1
Tablet	Oral	10 mg/1
Tablet	Oral	20 mg/1
Tablet	Oral	40 mg/1

Prices

Unit description	Cost	Unit
Pravachol 40 mg tablet	6.53USD	tablet
Pravachol 80 mg tablet	6.53USD	tablet
Pravastatin sodium 40 mg tablet	4.89USD	tablet
Pravastatin sodium 80 mg tablet	4.89USD	tablet
Pravachol 20 mg tablet	4.39USD	tablet
Pravachol 10 mg tablet	4.38USD	tablet
Pravastatin sodium 20 mg tablet	3.33USD	tablet
Pravastatin sodium 10 mg tablet	3.28USD	tablet
Apo-Pravastatin 40 mg Tablet	1.42USD	tablet
Co Pravastatin 40 mg Tablet	1.42USD	tablet
Jamp-Pravastatin 40 mg Tablet	1.42USD	tablet
Mint-Pravastatin 40 mg Tablet	1.42USD	tablet
Mylan-Pravastatin 40 mg Tablet	1.42USD	tablet
Novo-Pravastatin 40 mg Tablet	1.42USD	tablet
Pms-Pravastatin 40 mg Tablet	1.42USD	tablet
Pravachol 40 mg Tablet	1.42USD	tablet
Ran-Pravastatin 40 mg Tablet	1.42USD	tablet
Ratio-Pravastatin 40 mg Tablet	1.42USD	tablet
Sandoz Pravastatin 40 mg Tablet	1.42USD	tablet
Apo-Pravastatin 20 mg Tablet	1.18USD	tablet
Co Pravastatin 20 mg Tablet	1.18USD	tablet
Jamp-Pravastatin 20 mg Tablet	1.18USD	tablet
Mint-Pravastatin 20 mg Tablet	1.18USD	tablet
Mylan-Pravastatin 20 mg Tablet	1.18USD	tablet
Novo-Pravastatin 20 mg Tablet	1.18USD	tablet
Pms-Pravastatin 20 mg Tablet	1.18USD	tablet
Pravachol 20 mg Tablet	1.18USD	tablet
Ran-Pravastatin 20 mg Tablet	1.18USD	tablet
Ratio-Pravastatin 20 mg Tablet	1.18USD	tablet
Sandoz Pravastatin 20 mg Tablet	1.18USD	tablet
Apo-Pravastatin 10 mg Tablet	1.0USD	tablet
Co Pravastatin 10 mg Tablet	1.0USD	tablet
Jamp-Pravastatin 10 mg Tablet	1.0USD	tablet
Mint-Pravastatin 10 mg Tablet	1.0USD	tablet
Mylan-Pravastatin 10 mg Tablet	1.0USD	tablet
Novo-Pravastatin 10 mg Tablet	1.0USD	tablet
Pms-Pravastatin 10 mg Tablet	1.0USD	tablet
Pravachol 10 mg Tablet	1.0USD	tablet
Ran-Pravastatin 10 mg Tablet	1.0USD	tablet
Ratio-Pravastatin 10 mg Tablet	1.0USD	tablet
Sandoz Pravastatin 10 mg Tablet	1.0USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
CA1323836	No	1993-11-02	2010-11-02	Canada
US5622985	No	1994-10-22	2014-10-22	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	171.2 - 173°C	MSDS
water solubility	Soluble	FDA label
logP	0.59	FDA label

Predicted Properties

Property	Value	Source
Water Solubility	0.242 mg/mL	ALOGPS
logP	2.23	ALOGPS
logP	1.65	ChemAxon
logS	-3.2	ALOGPS
pKa (Strongest Acidic)	4.21	ChemAxon
pKa (Strongest Basic)	-2.7	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	6	ChemAxon
Hydrogen Donor Count	4	ChemAxon
Polar Surface Area	124.29 Å²	ChemAxon
Rotatable Bond Count	11	ChemAxon
Refractivity	113.6 m³·mol^-1	ChemAxon
Polarizability	46.56 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , negative	splash10-0uk9-0009000000-967b377abafe64b73071	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , negative	splash10-00di-0002900000-bd7fd66d793ae64426ff	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , negative	splash10-0udi-4809000000-0ed5a8797dfc49ecf5af	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , negative	splash10-0udi-2900000000-91b125182ce5d90f16ab	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , negative	splash10-0udi-1900000000-e8fc6384260de93c5aa8	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , negative	splash10-0udi-1900000000-11e99968bc0ba393b6f9	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , negative	splash10-0udi-4900000000-0e4265e6dc1468c1471d	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , negative	splash10-00di-0002900000-8795ee00dded0ef8be48	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , negative	splash10-0udi-3709000000-aa45be15af0471c0a46e	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , negative	splash10-0udi-2900000000-5617409991f5c58e5130	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , negative	splash10-0udi-2900000000-2bf5c13979a639625d1c	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , negative	splash10-0udi-2900000000-9a233e521607e82ab7a0	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , negative	splash10-0udi-0900000000-2083dfbb67bf2b03ccf9	View in MoNA
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-ITFT , negative	splash10-0uk9-0009000000-4b2c09a295ba7f3ce41b	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as medium-chain hydroxy acids and derivatives. These are hydroxy acids with a 6 to 12 carbon atoms long side chain.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Hydroxy acids and derivatives

Sub Class

Medium-chain hydroxy acids and derivatives

Direct Parent

Medium-chain hydroxy acids and derivatives

Alternative Parents

Fatty alcohols / Medium-chain fatty acids / Hydroxy fatty acids / Fatty acid esters / Branched fatty acids / Beta hydroxy acids and derivatives / Dicarboxylic acids and derivatives / Secondary alcohols / Carboxylic acid esters / Carboxylic acids

Substituents

Fatty alcohol / Medium-chain hydroxy acid / Medium-chain fatty acid / Beta-hydroxy acid / Branched fatty acid / Hydroxy fatty acid / Fatty acid ester / Fatty acyl / Dicarboxylic acid or derivatives / Secondary alcohol

Molecular Framework

Aliphatic homopolycyclic compounds

External Descriptors

statin (semi-synthetic), carboxylic ester, secondary alcohol, 3-hydroxy carboxylic acid, hydroxy monocarboxylic acid, carbobicyclic compound (CHEBI:63618 )

Targets

Details

1. 3-hydroxy-3-methylglutaryl-coenzyme A reductase

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Nadph binding
Specific Function:: Transmembrane glycoprotein that is the rate-limiting enzyme in cholesterol biosynthesis as well as in the biosynthesis of nonsterol isoprenoids that are essential for normal cell function including ubiquinone and geranylgeranyl proteins.
Gene Name:: HMGCR
Uniprot ID:: P04035
Molecular Weight:: 97475.155 Da

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Details

1. Cytochrome P450 2C8

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:: CYP2C8
Uniprot ID:: P10632
Molecular Weight:: 55824.275 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

2. Cytochrome P450 2C9

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:: CYP2C9
Uniprot ID:: P11712
Molecular Weight:: 55627.365 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

3. Cytochrome P450 2D6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:: CYP2D6
Uniprot ID:: P10635
Molecular Weight:: 55768.94 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

4. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Molecular Weight:: 57342.67 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

5. Cytochrome P450 3A5

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Oxygen binding
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:: CYP3A5
Uniprot ID:: P20815
Molecular Weight:: 57108.065 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Details

1. Solute carrier organic anion transporter family member 1B1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Sodium-independent organic anion transmembrane transporter activity
Specific Function:: Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:: SLCO1B1
Uniprot ID:: Q9Y6L6
Molecular Weight:: 76447.99 Da

References

Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150 ]
Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278 ]
Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]
Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22. [PubMed:15970799 ]
Sharma P, Holmes VE, Elsby R, Lambert C, Surry D: Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions. Xenobiotica. 2010 Jan;40(1):24-37. doi: 10.3109/00498250903351013. [PubMed:19919292 ]

Details

2. Solute carrier organic anion transporter family member 2B1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Sodium-independent organic anion transmembrane transporter activity
Specific Function:: Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:: SLCO2B1
Uniprot ID:: O94956
Molecular Weight:: 76709.98 Da

References

Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ: Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009 Feb;19(2):129-38. doi: 10.1097/FPC.0b013e32831bd98c. [PubMed:19151602 ]
Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. [PubMed:12724351 ]
Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. Epub 2003 Nov 10. [PubMed:14610227 ]

Details

3. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Molecular Weight:: 141477.255 Da

References

Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150 ]
Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]

Details

4. Solute carrier organic anion transporter family member 1A2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Sodium-independent organic anion transmembrane transporter activity
Specific Function:: Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:: SLCO1A2
Uniprot ID:: P46721
Molecular Weight:: 74144.105 Da

References

Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem. 1999 Dec 24;274(52):37161-8. [PubMed:10601278 ]

Details

5. Solute carrier family 22 member 6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Sodium-independent organic anion transmembrane transporter activity
Specific Function:: Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one molecule of endogenous dicarboxylic acid (glutarate, ketoglutarate, etc). Mediates the sodium-independent uptake of 2,3-dimercapto-1-propanesulfonic acid (DMPS) (By similarity). Mediates the sodium-in...
Gene Name:: SLC22A6
Uniprot ID:: Q4U2R8
Molecular Weight:: 61815.78 Da

References

Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777 ]

Details

6. Solute carrier family 22 member 8

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Sodium-independent organic anion transmembrane transporter activity
Specific Function:: Plays an important role in the excretion/detoxification of endogenous and exogenous organic anions, especially from the brain and kidney. Involved in the transport basolateral of steviol, fexofenadine. Transports benzylpenicillin (PCG), estrone-3-sulfate (E1S), cimetidine (CMD), 2,4-dichloro-phenoxyacetate (2,4-D), p-amino-hippurate (PAH), acyclovir (ACV) and ochratoxin (OTA).
Gene Name:: SLC22A8
Uniprot ID:: Q8TCC7
Molecular Weight:: 59855.585 Da

References

Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]
Ohtsuki S, Kikkawa T, Mori S, Hori S, Takanaga H, Otagiri M, Terasaki T: Mouse reduced in osteosclerosis transporter functions as an organic anion transporter 3 and is localized at abluminal membrane of blood-brain barrier. J Pharmacol Exp Ther. 2004 Jun;309(3):1273-81. Epub 2004 Feb 4. [PubMed:14762099 ]
Hasegawa M, Kusuhara H, Sugiyama D, Ito K, Ueda S, Endou H, Sugiyama Y: Functional involvement of rat organic anion transporter 3 (rOat3; Slc22a8) in the renal uptake of organic anions. J Pharmacol Exp Ther. 2002 Mar;300(3):746-53. [PubMed:11861777 ]

Details

7. Canalicular multispecific organic anion transporter 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Organic anion transmembrane transporter activity
Specific Function:: Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:: ABCC2
Uniprot ID:: Q92887
Molecular Weight:: 174205.64 Da

References

Chen C, Mireles RJ, Campbell SD, Lin J, Mills JB, Xu JJ, Smolarek TA: Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46. Epub 2004 Dec 22. [PubMed:15616150 ]
Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, Sugiyama Y: Biliary excretion of pravastatin in rats: contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter. Drug Metab Dispos. 1997 Oct;25(10):1123-9. [PubMed:9321514 ]
Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y: Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and Multidrug resistance-associated protein 2 (MRP2/ABCC2). J Biol Chem. 2002 Feb 22;277(8):6497-503. Epub 2001 Dec 17. [PubMed:11748225 ]
Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]

Details

8. Solute carrier family 22 member 11

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Sodium-independent organic anion transmembrane transporter activity
Specific Function:: Mediates saturable uptake of estrone sulfate, dehydroepiandrosterone sulfate and related compounds.
Gene Name:: SLC22A11
Uniprot ID:: Q9NSA0
Molecular Weight:: 59970.945 Da

References

Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]

Details

9. ATP-binding cassette sub-family G member 2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:: ABCG2
Uniprot ID:: Q9UNQ0
Molecular Weight:: 72313.47 Da

References

Suzuki M, Suzuki H, Sugimoto Y, Sugiyama Y: ABCG2 transports sulfated conjugates of steroids and xenobiotics. J Biol Chem. 2003 Jun 20;278(25):22644-9. Epub 2003 Apr 7. [PubMed:12682043 ]
Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y: Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther. 2005 Sep;314(3):1059-67. Epub 2005 May 18. [PubMed:15901800 ]

Details

10. Solute carrier family 22 member 7

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Sodium-independent organic anion transmembrane transporter activity
Specific Function:: Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:: SLC22A7
Uniprot ID:: Q9Y694
Molecular Weight:: 60025.025 Da

References

Khamdang S, Takeda M, Shimoda M, Noshiro R, Narikawa S, Huang XL, Enomoto A, Piyachaturawat P, Endou H: Interactions of human- and rat-organic anion transporters with pravastatin and cimetidine. J Pharmacol Sci. 2004 Feb;94(2):197-202. [PubMed:14978359 ]

Details

11. Monocarboxylate transporter 1

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Symporter activity
Specific Function:: Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Depending on the tissue and on cicumstances, mediates the import or export of lactic acid and ketone bod...
Gene Name:: SLC16A1
Uniprot ID:: P53985
Molecular Weight:: 53943.685 Da

References

Tamai I, Takanaga H, Maeda H, Ogihara T, Yoneda M, Tsuji A: Proton-cotransport of pravastatin across intestinal brush-border membrane. Pharm Res. 1995 Nov;12(11):1727-32. [PubMed:8592677 ]

Details

12. Bile salt export pump

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Transporter activity
Specific Function:: Involved in the ATP-dependent secretion of bile salts into the canaliculus of hepatocytes.
Gene Name:: ABCB11
Uniprot ID:: O95342
Molecular Weight:: 146405.83 Da

References

Morisawa Y, Takikawa H: Effect of bile acids on the biliary excretion of pravastatin in rats. Hepatol Res. 2009 Jun;39(6):595-600. doi: 10.1111/j.1872-034X.2009.00493.x. Epub 2009 Feb 24. [PubMed:19260999 ]

Details

13. Solute carrier organic anion transporter family member 1B3

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrate

General Function:: Sodium-independent organic anion transmembrane transporter activity
Specific Function:: Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:: SLCO1B3
Uniprot ID:: Q9NPD5
Molecular Weight:: 77402.175 Da

References

Link [Link]

Drug created on June 13, 2005 07:24 / Updated on July 18, 2017 16:46

Get DrugBank to go!

Structure for DB00175 (Pravastatin)

Targets

References

Enzymes

References

References

References

References

References

Transporters

References

References

References

References

References

References

References

References

References

References

References

References

References